$14.70
6.52% today
Nasdaq, May 20, 08:26 pm CET
ISIN
US0453961080
Symbol
ASMB
Sector
Industry

Assembly Biosciences, Inc. Stock price

$13.80
+3.86 38.83% 1M
-1.54 10.04% 6M
-1.98 12.55% YTD
-1.16 7.75% 1Y
-5.76 29.45% 3Y
-227.28 94.28% 5Y
-156.24 91.88% 10Y
Nasdaq, Closing price Mon, May 19 2025
+0.38 2.83%
ISIN
US0453961080
Symbol
ASMB
Sector
Industry

Key metrics

Market capitalization $105.40m
Enterprise Value $17.39m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.54
P/S ratio (TTM) P/S ratio 3.28
P/B ratio (TTM) P/B ratio 3.88
Revenue growth (TTM) Revenue growth 148.33%
Revenue (TTM) Revenue $32.15m
EBIT (operating result TTM) EBIT $-44.63m
Free Cash Flow (TTM) Free Cash Flow $-56.21m
Cash position $91.03m
EPS (TTM) EPS $-6.24
P/S forward 2.93
EV/Sales forward 0.48
Short interest 0.25%
Show more

Is Assembly Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Assembly Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Assembly Biosciences, Inc. forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Assembly Biosciences, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Assembly Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
32 32
148% 148%
100%
- Direct Costs 0.13 0.13
64% 64%
0%
32 32
154% 154%
100%
- Selling and Administrative Expenses 18 18
19% 19%
55%
- Research and Development Expense 59 59
27% 27%
183%
-45 -45
20% 20%
-138%
- Depreciation and Amortization 0.13 0.13
64% 64%
0%
EBIT (Operating Income) EBIT -45 -45
20% 20%
-139%
Net Profit -40 -40
22% 22%
-124%

In millions USD.

Don't miss a Thing! We will send you all news about Assembly Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Assembly Biosciences, Inc. Stock News

Neutral
GlobeNewsWire
12 days ago
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 –
Neutral
GlobeNewsWire
13 days ago
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection markers by ABI-4334, currently in Phase 1b with data anticipated in the first half of 2025 – SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a b...
Neutral
GlobeNewsWire
about one month ago
– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations –
More Assembly Biosciences, Inc. News

Company Profile

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jason Okazaki
Employees 73
Founded 2005
Website www.assemblybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today